

## Relevance of brain MRI in patients with uveitis: retrospective cohort on 402 patients

### *Running title: Diagnosis value of brain MRI in patients with uveitis*

N. Chirpaz<sup>1,2</sup>, S. Kerever<sup>\*3</sup>, A. Gavaille<sup>\*1</sup>, L. Kodjikian<sup>2,4</sup>, R. Bernier<sup>1,2</sup> M. Gerfaud-Valentin<sup>1</sup>,  
P. Denis<sup>2</sup>, T. Mathis<sup>2</sup>, Y. Jamilloux<sup>1</sup>, P.Sève<sup>1,4,5</sup>

1 Department of Internal Medicine, Hôpital de la Croix Rousse, Hospices Civils de Lyon , F-69004, Lyon, France

2 Department of Ophthalmology, Croix-Rousse Teaching Hospital, Hospices Civils de Lyon, Lyon, France

3 Department of Anesthesiology and Critical Care, Lariboisière University Hospital, AP-HP, University of Paris France.

4 UMR-CNRS 5510 Matéis, Villeurbanne, Université Claude Bernard Lyon 1, University of Lyon, Lyon, France

5 Hospices Civils de Lyon, Pôle IMER, Lyon, F-69003, France ; Univ. Lyon, University Claude Bernard Lyon 1, HESPER EA 7425, F-69008 Lyon, France

\*contributed equally to this work

**Corresponding author:** Prof. Pascal Sève, Department of Internal Medicine, Hôpital de la Croix-Rousse, 103 grande rue de la Croix-Rousse, F-69004, Lyon, France.

Tel: +33 426 732 636 - Fax: +33 426 732 637 - E-mail: [pascal.seve@chu-lyon.fr](mailto:pascal.seve@chu-lyon.fr)

## **Synopsis**

Although brain magnetic resonance imaging (bMRI) is frequently performed as part of the etiological assessment of uveitis, very few prior studies have evaluated the relevance of this exam.

## Abstract

### Aim

To assess the diagnostic value of brain magnetic resonance imaging (bMRI) for the etiological diagnosis of uveitis and to establish predictive factors associated with its advantageous use.

### Methods

Retrospective study on all patients with *de novo* uveitis who were referred to our tertiary hospital and who underwent a bMRI between 2003 and 2018. The bMRI was considered useful if it served to confirm a diagnosis or correct a misdiagnosis. We also collected characteristics of uveitis and associated ophthalmological and neurological clinical signs.

### Results

Brain MRI was contributive in 19 out of 402 cases (5%): 10 multiple sclerosis, 5 radiologically isolated syndromes, and 4 oculocerebral lymphomas.

A total of 34 (8%) had neurological signs and 13 (38%) of those patients had a contributive bMRI. Meanwhile, in the absence of neurological signs, 1% of bMRIs were contributive, and none of them resulted in specific treatment.

Among patients with a contributive bMRI, 68% had neurological signs. Univariate analysis established that neurological signs ( $p<0.001$ ), granulomatous uveitis ( $p=0.003$ ), retinal vasculitis ( $p=0.002$ ), and intermediate uveitis ( $p<0.001$ ) were all significantly associated with a contributive bMRI. Multivariate analysis confirms the significant association of neurological signs ( $p<0.001$ ) and intermediate uveitis ( $p=0.01$ ).

Patients with oculocerebral lymphoma were significantly older ( $p<0.001$ ) and all were above 40 years of age.

### Conclusion

Brain MRI appears to be a relevant and contributive exam, but it should be performed in cases of intermediate/posterior uveitis or panuveitis accompanied by neurological signs, retinal vasculitis, or in patients older than 40, to rule out an oculocerebral lymphoma.

**Keywords:** brain magnetic resonance imaging, uveitis, multiple sclerosis, oculocerebral lymphoma, retinal vasculitis

## Introduction

Uveitis is an intraocular inflammation that affects both the uveal tract and adjacent structures such as the vitreous and the retina. It is the third cause of blindness worldwide and currently accounts for approximately 10% of preventable vision loss in the United States and up to 15% worldwide [1,2]. The underlying causes are multiple and mainly represented by inflammatory diseases, followed by pure ophthalmological entities and infectious diseases [3,4].

Although the etiological diagnosis of uveitis is important for prognosis and therapeutics, the etiology remains uncertain or unknown in 28 to 45% of cases [1,5–7], depending on the anatomic type of uveitis. Due to the multiple underlying causes and its heterogeneous presentation, etiological diagnosis is a challenge for patient care and health economics [1,8]. So far, the utility of diagnostic tests has mainly been evaluated in retrospective studies and often in isolated or separate manner [9,10]. One prospective study named ULISSE (Uveitis: clinical and medicoeconomic evaluation of a standardized strategy for etiological diagnosis) has shown that a standardized strategy for the etiological diagnosis of uveitis was neither inferior nor superior to an open strategy [11]. Subsequent analysis has shown that only a few diagnostic tests were useful for the etiological assessment of uveitis [12,13]. These were often cheap, simple, usually guided by clinical findings, and resulted in an etiological diagnosis for many patients.

The benefits of invasive as well as more complex investigations such as brain magnetic resonance imaging (bMRI) could not be determined since these tests were rarely performed. Only a few studies have assessed the diagnostic value of bMRI in uveitis patients [9,14] and to date, patients who may benefit from this exam have not been clearly defined.

In this study, our aim was to assess the usefulness of MRI in the etiological diagnosing of uveitis in a large cohort of patients and to establish predictive factors associated with its advantageous use.

## **PATIENTS AND METHODS**

### **Patients**

This study was a retrospective analysis of the records of 1,214 patients with “uveitis” referred by the Department of Ophthalmology (Lyon University Hospital, Lyon, France) or referred by non-hospital ophthalmologists to the department of Internal Medicine (Lyon University Hospital, Lyon, France) between January 2003 and July 2018. The uveitis diagnosis was always confirmed by an ophthalmological examination. Cases of uveitis occurring in the course of previously-diagnosed diseases were excluded. This study was approved by the ethics committee of the French Society of Ophthalmology (IRB 00008855 Société Française d’Ophtalmologie IRB#1).

### **Diagnostic work-up and definitions**

All the patients underwent a standard screening protocol for uveitis, which included a C-reactive protein test, a complete blood cell count (CBC), a serological test for syphilis, and a chest X-ray [3,11]. Human leucocyte antigen typing (HLA)-B27 was performed in patients with acute anterior uveitis. In patients with chronic anterior uveitis or granulomatous uveitis, a measurement of blood angiotensin-converting enzyme (ACE), a tuberculin intradermal reaction and/or a QuantiFERON TB Gold Plus test, and a chest computerized tomography (CT) scan were performed.

Diagnostic screening for sarcoidosis included conjunctival or skin biopsies if there were clinically suggestive features. Some patients underwent a minor salivary gland biopsy (MSGB), a transbronchial lung biopsy, a bronchoalveolar lavage (BAL) or a PET-scan imaging. This work-up was completed in some patients by an anterior chamber paracentesis (with a polymerase chain reaction for Herpes virus, *Toxoplasma* or RNA16S, and sometimes an interleukin-10 measurement), and/or a vitreous biopsy.

bMRI and lumbar puncture were mostly performed in the presence of intermediate or

posterior uveitis, or panuveitis. Brain MRI was considered contributive when there were useful findings for etiological diagnosis, and non-contributive when it was normal or in the presence of non-specific abnormalities unrelated to the etiology.

The Standardization of Uveitis Nomenclature was used throughout this study for the anatomical classification of uveitis [4,15].

Briefly, the diagnostic criteria used were the following:

- the international study group for Behcet's disease criteria [16];
- the Levinson's criteria [17] or the global diagnostic criteria for birdshot retinochoroidopathy. All birdshot retinochoroidopathy were HLA-A29 positive;
- the 2010 revised McDonald's criteria for multiple sclerosis (MS) [18] and Okuda's criteria for radiologically isolated syndromes (RIS), defined as asymptomatic subjects with bMRI abnormalities suggestive of MS [19]. All MS or RIS diagnoses were made in conjunction with a neurologist.
- the international criteria for the diagnosis of sarcoidosis [20] (with Zajicek's classification for neurosarcoidosis) [21]. In the absence of histological proof, we used Abad's modified criteria [22]. Patients were presumed to have sarcoid uveitis if they had at least 2 of the following 4 criteria: typical changes on chest X-ray or CT scan, a predominantly CD4 lymphocytosis on BAL fluid analysis, an elevated ACE or an 18-fluorodeoxyglucose (18-FDG) uptake on scintigraphy. They were judged to have undetermined sarcoid uveitis when only one criterion was met.
- the Assessment of SpondyloArthritis international Society (ASAS) criteria for spondyloarthritis [23]. HLA-B27 positive patients with acute non-granulomatous anterior uveitis without clinical and/or radiological features of spondyloarthritis were diagnosed as having HLA-B27-related anterior uveitis;
- the revised diagnostic criteria for Vogt-Koyanagi-Harada (VKH) disease [24];
- Gupta's criteria for the diagnosis of intraocular tuberculosis [25].

Whenever the intraocular inflammation could not be assigned to a specific diagnosis, the uveitis was considered to be idiopathic.

### **Data collection**

We collected patients' demographic data, follow-up times, and the following ophthalmological characteristics at diagnosis: anatomical type of uveitis (anterior, intermediate, posterior, pan uveitis) [11] and anterior chamber examination (tonometry, slit lamp, biomicroscopy to assess whether the uveitis was granulomatous or not). We also reported whether the uveitis was acute or chronic, and uni- or bilateral.

### **Statistical analysis**

The data are described as their frequencies and percentages for the categorical variables, and as their medians (25th–75th percentile range) for the quantitative variables. Categorical variables were compared using the Chi-square test or the Fisher exact test, as appropriate, and quantitative variables using Wilcoxon's ranked-sum test. After assessment of possible colinearity between variables by using variance inflation factor, the logistic regression model was built by using backward stepwise selection method with contributive bMRI as the dependent variable. Independent and clinically relevant predictors selected from univariate analysis ( $p < 0.2$ ) were entered into the model by using rule of 10 events per variable.

All tests were two-sided and statistical significance was set at the  $p = 0.05$  level. Analyses were performed using R open source software 3.4.4 (available online at <http://www.R-project.org>).

## RESULTS

### Patients characteristics

After excluding 312 patients because of insufficient/missing data, 903 patients were included, of whom 402 patients (44.5%) underwent a bMRI. Baseline characteristics of these 402 patients are summarized in Table 1. Overall, the mean age at diagnosis was 49 years (range, 31-62) and 230 were women (57%). Sixty-four patients (16%) were non-Caucasians, including patients from North Africa (12%), Sub-Saharan Africa (2%) and Asia (1%).

The anatomical distribution of uveitis was: anterior uveitis (AU, 11%), intermediate uveitis (IU, 30%), posterior uveitis (PU, 33%), or panuveitis (UP, 27%). Among the 402 patients, 68% had a bilateral disease and 84% had a chronic course. Most were non-hypertensive (94%) or non-granulomatous (77%). Unilateral papillitis was present in 83 cases (21%), and bilateral papillitis in 36 cases (9%). Thirty four patients (8%) had one or more neurological manifestations before or at the time of the bMRI test: 7 cranial nerve impairments, 7 motor impairments, 5 sensitive impairments, 4 optic neuropathies, 3 cerebellar syndromes, 2 states of mental confusions, 2 seizures, 1 frontal syndrome, 1 nystagmus, 1 peripheral neuropathy and 1 atypical headache.

### Relevance of bMRI

bMRI was considered to be abnormal in 80 cases (20%), including 26 with non-specific hypersignals (32%), 34 with vascular leucopathy (43%), 16 with demyelinating lesions (20%), and 4 with parenchymal mass (5%). bMRI was considered to be contributive in 19 cases (5%). An abnormal bMRI led to the diagnosing of 10 cases of MS, 5 RIS, and 4 oculocerebral lymphomas (OCL) (Table 2).

Features associated with a contributive bMRI are summarized in Table 3. Among patients with a contributive bMRI, 13 (68%) had neurological signs, 9 (47%) had retinal vasculitis, and 1 (5%) had periphlebitis. In the non-contributive group, 21 patients (5%) had neurological



signs, 61 (16%) presented retinal vasculitis, and one (0,3%) had periphlebitis. Cases with contributive MRI are detailed in Table 2.

Uveitis remained of undetermined origin in 27 cases in spite of bMRI abnormalities.

Among patients with neurological signs, 13 (38%) had a contributive bMRI. In the absence of neurological signs, only 6 patients had a contributive bMRI with 1% leading to a diagnosis: 5 RIS, and 1 OCL. Only the patient with OCL received a specific treatment after this diagnosis.

In the univariate analysis, a contributive bMRI was associated with the following features: intermediate uveitis ( $p<0.001$ ), presence of retinal vasculitis ( $p=0.002$ ), granulomatous type ( $p=0.003$ ), and presence of neurological signs ( $p<0.001$ ) (Table 4).

In the multivariate regression analysis, the main features independently associated with having a contributive bMRI were: intermediate uveitis ( $p=0.01$ ) and the presence of neurological signs ( $p<0.001$ ) (Table4).

Patients with MS and RIS-related uveitis were non-significantly younger ( $p=0.05$ ), with a median age of 38. While patients with OCL were significantly older ( $p<0.001$ ) with a median age of 67, they were all above 40 years of age (Table 5), ranging from 55 to 88 years old.

## Discussion

The value of bMRI for the etiological diagnosis of uveitis is not well defined. In the present study, we found a minority (5%) of patients who underwent a bMRI had abnormalities contributive to etiological diagnosing. Among subjects free of neurological signs, bMRI was abnormal in only few cases (1%), leading to a diagnosis of either RIS or OCL. Since bMRI is an expensive exam [8] sometimes associated with side effects such as allergy and not always easily accessible, it should not be prescribed for all patients with unexplained uveitis. In a previous study, Hadjadj et al. reported that the presence of snowballs in the vitreous humor and retinal vasculitis were among the features associated with abnormal bMRI [9]. Because abnormal MRI features are often nonspecific, we chose to assess the relevance of MRI abnormalities in the etiological diagnosing of uveitis. Our work shows that intermediate uveitis, retinal vasculitis, granulomatous uveitis, and the presence of neurological signs were all significantly related to a contributive bMRI.

In the ULISSE study [11], a bMRI was performed in 44 patients, and was contributive in 16% of the cases. A retrospective study of 71 patients with intermediate/posterior uveitis, or panuveitis showed that a systematic bMRI was contributive in 8% of the cases [14]. Hadjadj et al. reported similar results: a brain MRI was performed in 168 patients and was contributive in 15 patients (8.9%), among whom only three presented neurological symptoms. Abnormal findings were most often demyelinating lesions. They reported that bMRI led to the diagnosis of neurosarcoidosis in 4 cases and Behçet's disease in 1 patient. Like other authors, we consider that asymptomatic demyelinating lesions in patients with sarcoidosis and Behçet's disease should not lead to the start of a systemic treatment.

In our study, MS was the main diagnosis in patients with contributive bMRI. For the most part, uveitis is known to precede the diagnosis of MS [26]. However only 1% of MS uveitis patients will present an uveitis, which explains why it is not used as a diagnostic criterion for MS. Several studies have shown a prevalence of MS ranging from 7% to 30% in patients

with intermediate uveitis, leading the authors to suggest systematic bMRI for these patients [27].

For Petrushkin et al. bMRI should not be proposed in the absence of a history or clinical signs suggestive of MS, nor in the absence of prognostic or therapeutic consequences [27].

Five of our contributive bMRI tests led to the diagnosing of RIS. Among this subgroup of patients who have asymptomatic demyelinating lesions which are highly suggestive of MS, one-third may convert to clinically-established MS within 5 years [28]. RIS diagnosis today leads to a strict follow-up alone, although some trials (TERIS and ARISE studies) are ongoing to evaluate MS oral therapy in these cases so as to delay the onset of the first clinical event [29,30].

OCL is a rare disease that can manifest as an intermediate/posterior uveitis or as panuveitis. It is thus essential to rule out this diagnosis in potential cases because OCL is a life-threatening condition. In suspected cases, a bMRI is generally suggested (with T1 sequences before and after injection of contrast material) to explore a lymphomatous parenchymal mass. In our study, 4 patients had OCL with a contributive MRI, including 3 patients with neurological symptoms. All patients were over 40 and had chronic intermediate/posterior uveitis or panuveitis.

In a previous study, we had developed recommendations for the diagnosing of uveitis based on a review of the literature and the findings of the ULISSE study [31]. We proposed that bMRI should be reserved for patients over 40 presenting unexplained uveitis, when searching for cerebral lesions suggestive of OCL. In our study OCL patients were significantly older than the general population, and this therefore reinforces our previous recommendations.

In addition to these recommendations, Winkelmann al. recommended performing bMRI before testing for monoclonal anti-TNF $\alpha$  antibodies, due to the risk of aggravating a

demyelinating disease [32]. For the same reasons, Wakefield et al. recommended that bMRI be done before giving anti-TNF $\alpha$  or anti-IL6 therapy to patients with intermediate uveitis [33]. In our study, bMRI frequently pinpointed hypersignals which were either non-specific, or linked to white matter hyperintensities of vascular origin or inflammatory lesions. Nonetheless bMRI interpretation in these cases can be difficult and may depend on the operator, with frequent errors at risk. Neurological expertise and lumbar puncture should be offered, to examine the link between MRI abnormalities and uveitis etiology. Nearly 99% of the bMRIs performed in the absence of neurological signs were non-contributive. Patients with no neurological signs but with contributive bMRIs can be split into two groups: the first covers RIS patients with no specific treatment requirements, and the second covers OCL patients who were all older than 40.

Our work established an inverse correlation between posterior uveitis and a contributive MRI. This may be explained by a small number contributive MRIs, since MS/RIS and OCL uveitis are usually intermediate [34,35]. Moreover, as recommended by the SUN [15], uveitis was classified as intermediate when the vitreous was the major site of inflammation even if there was posterior uveitis. However, since posterior and panuveitis are common manifestations of OCL, it appears essential in these situations to rule out this etiology.

There are some limitations to our study. First, this study is retrospective and monocentric, and bMRI was not performed in all cases. Second, because of its retrospective nature this study suffers from a reporting bias: indeed the clinical examination was not standardized, and this may explain the low rate of papillary edema, cystoid macular edema and periphlebitis. Third, since our center is a tertiary referral center for the management of uveitis, some patients had a long history of uveitis before being referred to us, and thus could differ from daily-care patients. However, this last point also made it possible to include patients with sufficient follow-up after initial diagnosis. Fourth, patients in this study were referred by ophthalmologists to internists according to no pre-established criteria, but mainly for cases of ophthalmological presentation suggestive of systemic disease. This may have

biased the patient selection, leading to over-representation of systemic diseases. Finally, the bMRI analysis was not standardised by a radiologist blinded to the patient's clinical history.

## **Conclusion**

In conclusion, our study shows that in the context of etiological uveitis diagnosing, bMRI is relevant in two specific situations: in patients with neurological signs and/or retinal vasculitis, and in patients older than 40 years with intermediate/posterior uveitis or panuveitis. Given the cost of bMRI, we suggest limiting examinations to patients presenting with at least one of these features. The most important diagnoses to look for are multiple sclerosis, in the first case, and oculocerebral lymphoma in the second. Further controlled studies with larger numbers of patients are needed to confirm our results and to clarify the clinical usefulness of bMRI in patients with uveitis of unknown origin.

**CONFLICT OF INTEREST STATEMENT:** The authors have no conflict of interest to declare.

**Contributors:** NC, PS, TM and AG were the principal investigators who conceived and designed the study. NC and RB collected data. SK performed statistical analysis. All authors interpreted the data and approved the manuscript. NC and AG drafted the manuscript. PS, TM, YJ, SK and LK revised the manuscript.

**Funding:** This research received no funding.

**Ethics approval:** This study was approved by the ethics committee of the French Society of Ophthalmology (IRB 00008855 Société Française d'Ophtalmologie IRB#1)

## REFERENCES

- 1 Bodaghi B, Cassoux N, Wechsler B, *et al.* Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. *Medicine (Baltimore)* 2001;80:263–70. doi:10.1097/00005792-200107000-00005
- 2 Nussenblatt RB. The natural history of uveitis. *Int Ophthalmol* 1990;14:303–8.
- 3 Bertrand P-J, Jamilloux Y, Ecochard R, *et al.* Uveitis: Autoimmunity... and beyond. *Autoimmun Rev* 2019;18:102351. doi:10.1016/j.autrev.2019.102351
- 4 Selmi C. Diagnosis and classification of autoimmune uveitis. *Autoimmun Rev* 2014;13:591–4. doi:10.1016/j.autrev.2014.01.006
- 5 Rothova A, Buitenhuis HJ, Meenken C, *et al.* Uveitis and systemic disease. *Br J Ophthalmol* 1992;76:137–41. doi:10.1136/bjo.76.3.137
- 6 Smit RL, Baarsma GS, de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. *Int Ophthalmol* 1993;17:71–6.
- 7 Tran VT, Auer C, Guex-Crosier Y, *et al.* Epidemiological characteristics of uveitis in Switzerland. *Int Ophthalmol* 1994;18:293–8.
- 8 Lee CS, Randhawa S, Lee AY, *et al.* Patterns of Laboratory Testing Utilization Among Uveitis Specialists. *Am J Ophthalmol* 2016;170:161–7. doi:10.1016/j.ajo.2016.08.004
- 9 Hadjadj J, Dechartres A, Chapron T, *et al.* Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. *Autoimmun Rev* 2017;16:504–11. doi:10.1016/j.autrev.2017.03.006
- 10 Pelegrín L, Hernández-Rodríguez J, Espinosa G, *et al.* Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. *Autoimmun Rev* 2017;16:237–43. doi:10.1016/j.autrev.2017.01.006
- 11 de Parisot A, Kodjikian L, Errera M-H, *et al.* Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). *Am J Ophthalmol* 2017;178:176–85. doi:10.1016/j.ajo.2017.03.029
- 12 Abad S, Sève P, Dhote R, *et al.* [Guidelines for the management of uveitis in internal medicine]. *Rev Med Interne* 2009;30:492–500. doi:10.1016/j.revmed.2008.08.011
- 13 Grumet P, Kodjikian L, de Parisot A, *et al.* Contribution of diagnostic tests for the etiological assessment of uveitis, data from the ULISSE study (Uveitis: Clinical and medicoeconomic evaluation of a standardized strategy of the etiological diagnosis). *Autoimmun Rev* 2018;17:331–43. doi:10.1016/j.autrev.2017.10.018
- 14 Gil H, Fery-Blanco C, Schwartz C, *et al.* [Contribution of cerebral magnetic resonance imaging to etiological investigation of uveitis]. *Rev Med Interne* 2014;35:790–3. doi:10.1016/j.revmed.2014.04.008

- 15 Jabs DA, Nussenblatt RB, Rosenbaum JT, *et al.* Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol* 2005;140:509–16.
- 16 Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. *Lancet* 1990;335:1078–80.
- 17 Levinson RD, Brezin A, Rothova A, *et al.* Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. *Am J Ophthalmol* 2006;141:185–7. doi:10.1016/j.ajo.2005.08.025
- 18 Polman CH, Reingold SC, Banwell B, *et al.* Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011;69:292–302. doi:10.1002/ana.22366
- 19 Okuda DT, Mowry EM, Beheshtian A, *et al.* Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. *Neurology* 2009;72:800–5. doi:10.1212/01.wnl.0000335764.14513.1a
- 20 Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. *Eur Respir J* 1999;14:735–7. doi:10.1034/j.1399-3003.1999.14d02.x
- 21 Zajicek JP, Scolding NJ, Foster O, *et al.* Central nervous system sarcoidosis--diagnosis and management. *QJM* 1999;92:103–17. doi:10.1093/qjmed/92.2.103
- 22 Abad S, Meyssonier V, Allali J, *et al.* Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients. *Arthritis Rheum* 2004;51:974–82. doi:10.1002/art.20839
- 23 Rudwaleit M, van der Heijde D, Landewé R, *et al.* The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis* 2011;70:25–31. doi:10.1136/ard.2010.133645
- 24 Read RW, Holland GN, Rao NA, *et al.* Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. *Am J Ophthalmol* 2001;131:647–52. doi:10.1016/s0002-9394(01)00925-4
- 25 Gupta A, Sharma A, Bansal R, *et al.* Classification of intraocular tuberculosis. *Ocul Immunol Inflamm* 2015;23:7–13. doi:10.3109/09273948.2014.967358
- 26 Cunningham ET, Pavesio CE, Goldstein DA, *et al.* Multiple Sclerosis-Associated Uveitis. *Ocul Immunol Inflamm* 2017;25:299–301. doi:10.1080/09273948.2017.1334469
- 27 Petrushkin H, Kidd D, Pavesio C. Intermediate uveitis and multiple sclerosis: to scan or not to scan. *Br J Ophthalmol* 2015;99:1591–3. doi:10.1136/bjophthalmol-2015-307269
- 28 Yamout B, Al Khawajah M. Radiologically isolated syndrome and multiple sclerosis. *Mult Scler Relat Disord* 2017;17:234–7. doi:10.1016/j.msard.2017.08.016



- 29 Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome - Full Text View - ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT03122652> (accessed 17 Dec 2019).
- 30 Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) - Full Text View - ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02739542> (accessed 17 Dec 2019).
- 31 Sève P, Bodaghi B, Trad S, *et al.* [Uveitis: Diagnostic work-up. Recommendations from an expert committee]. *Rev Med Interne* 2018;39:676–86. doi:10.1016/j.revmed.2017.09.015
- 32 Winkelmann A, Patejdl R, Wagner S, *et al.* Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. *J Neurol* 2008;255 Suppl 6:109–14. doi:10.1007/s00415-008-6020-z
- 33 Wakefield D, McCluskey P, Wildner G, *et al.* Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. *Autoimmun Rev* 2017;16:213–22. doi:10.1016/j.autrev.2017.01.003
- 34 Olsen TG, Frederiksen J. The association between multiple sclerosis and uveitis. *Surv Ophthalmol* 2017;62:89–95. doi:10.1016/j.survophthal.2016.07.002
- 35 Kimura K, Usui Y, Goto H, *et al.* Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. *Jpn J Ophthalmol* 2012;56:383–9. doi:10.1007/s10384-012-0150-7

## Tables

Table 1: General characteristics, ophthalmological findings and etiological distribution in 402 patients

<b>Gender</b>	
Female	230 (57%)
Male	172 (43%)
<b>Ethnicity</b>	
Caucasian	338 (84%)
North African	50 (12%)
Sub-Saharan	7 (2%)
Asian	5 (1%)
Others	2 (0.5%)
<b>Age</b>	
years*	49 [33 ; 63]
<b>Characteristic of uveitis</b>	
Bilateral	275 (68%)
Chronic	337 (84%)
Granulomatous	93 (23%)
Hypertensive	23 (6%)
<b>Anatomical type</b>	
Anterior	43 (11%)
Intermediate	119 (30%)
Posterior	131 (33%)
Panuveitis	109 (27%)
<b>Associated clinical signs</b>	
Vasculitis	70 (17%)
Macular oedema	66 (16%)
Unilateral papillary oedema / papillitis	83 (21%)
Billateral papillary oedema / papillitis	36 (9%)
Periphlebitis	2 (0.5%)
<b>Aetiology</b>	
Idiopathic	173 (43%)
<b>Systemic diseases</b>	109 (27%)
Sarcoïdosis	68 (17%)
Histologically-prooven sarcoidosis	22 (5%)
Vogt-Koyanagi-Harada	5 (1%)
Radiologically isolated syndromes/Multiple Sclerosis	15 (4%)
Behçet's disease	8 (2%)
HLA-B27-related uveitis	13 (3%)
<b>Ophthalmological entities</b>	76 (19%)
Birdshot retinochoroidopathy	24 (6%)

Fuchs' heterochromic cyclitis	9 (2%)
Whites dots <sup>1</sup>	18 (4%)
Others	25 (6%)
<b>Infectious</b>	29 (7%)
Tuberculosis	19 (5%)
Lyme disease	6 (1%)
Syphilis	2 (0.5%)
Herpes	2 (0.5%)
<b>Others</b>	
Lymphoma	14 (3%)
Iatrogenous	1 (0.2%)

Data are expressed as number and percentage, n (%), or \* median [1st; 3rd quartile].

<sup>1</sup> including: 10 multifocal choroiditis, 7 Acute posterior multifocal placoid pigment epitheliopathy and 1 multiple evanescent white dot syndrome

Table 2: General characteristics, ophthalmological findings of patients with a contributive cerebral

Age	Sex	Uveitis anatomy	Ophthalmologic signs	B	C	G	Diagnosis	Neurological sign	bMRI	Treatment
20	M	Pan-U	retinal vasculitis	X	X		MS	sensitive and motor impairment optic neuropathy	inflammatory hypersignals <sup>1</sup>	yes (azathioprine)
32	M	IU		X	X	X	MS	motor impairment optic neuropathy	inflammatory hypersignals <sup>1</sup>	yes (copaxone)
26	M	IU	retinal vasculitis	X	X		RIS		inflammatory hypersignals <sup>2</sup>	no
36	W	UP	retinal vasculitis	X	X		RIS		inflammatory hypersignals <sup>2</sup>	no
67	W	UP			X		OCL		parietal and occipital lymphoma	yes (chemotherapy + ocular radiotherapy)
33	M	IU		X	X	X	MS	motor impairment	inflammatory hypersignals <sup>1</sup>	yes (refused)
35	W	Pan-U	retinal vasculitis	X	X	X	MS	sensitive and motor impairment	inflammatory hypersignals <sup>1</sup>	yes (azathioprine)
26	W	IU	retinal vasculitis	X	X		MS	motor impairment	Inflammatory hypersignals <sup>1</sup>	yes (corticoids boluses + azathioprine)
57	M	IU	retinal vasculitis		X		OCL	confusion	thalamic lymphoma	yes (chemotherapy)
28	W	IU	retinal vasculitis		X	X	RIS		inflammatory hypersignals <sup>2</sup>	no

43	W	Pan-U		X	X	X	RIS		inflammatory hypersignals <sup>2</sup>	no
46	W	Pan-U	retinal vasculitis macular edema	X	X	X	MS	optic neuropathy	inflammatory hypersignals <sup>1</sup>	yes (azathioprine)
60	W	IU		X	X	X	OCL	frontal syndrome	frontal lymphoma	yes (chemotherapy)
68	W	IU		X	X	X	OCL	cerebellar syndrome	lymphoma	yes (unknown)
38	W	IU	periphlebitis		X		MS	sensitive impairment	inflammatory hypersignals <sup>1</sup>	yes (refused)
29	W	IU		X	X	X	MS	sensitive impairment	inflammatory hypersignals <sup>1</sup>	yes (mycophenolate mofetil)
56	W	Pan-U		X			RIS	0	inflammatory hypersignals <sup>2</sup>	no
56	W	IU	retinal vasculitis				MS	optic neuropathy	inflammatory hypersignals <sup>1</sup>	yes (azathioprine)
43	W	IU				X	MS	sensitive impairment	inflammatory hypersignals <sup>1</sup>	yes (azathioprine)

A: acute, bMRI :brain magnetic resonance imaging; B: bilateral, G: granulomatous, MO: macular oedema ; MS: multiple sclerosis; OCL: oculocerebral lymphoma; RIS: radiologically isolated syndromes; RV: retinal vasculitis ; U: unilateral

<sup>1</sup>: According to 2010 revised McDonald's criteria

<sup>2</sup>: According to Okuda's criteria

Table 3: General characteristics and ophthalmological findings according to normal or abnormal bMRI (n=402)

		Non Contributive bMRI (n=383)	Contributive bMRI (n=19)	p-value
Age (years)*		49 [32 ; 64]	43 [34 ; 56]	0.37
Sex (n,%)	Female	216 (56.4%)	14 (73.7%)	0.16
Ethnic group (n,%)	North Africa	45 (11.7%)	5 (26.3%)	0.37
	Sub-Saharan Africa	7 (1.8%)	0 (0.0%)	
	Caucasian	324 (84.6%)	14 (73.7%)	
	Other	7 (1.8%)	0 (0.0%)	
<b>Characteristics of uveitis</b>				
	Bilateral	262 (68.4%)	13 (68.4%)	1.00
	Chronic	319 (83.3%)	18 (94.7%)	0.334
	Granulomatous	83 (21.7%)	10 (52.6%)	0.004
	Hypertensive	23 (6.0%)	0 (0.0%)	0.613
<b>Anatomical type</b>	Anterior uveitis	43 (11.2%)	0 (0.0%)	0.24
	Intermediate uveitis	106 (27.7%)	13 (68.4%)	0.0004
	Posterior uveitis	130 (33.9%)	1 (5.3%)	0.01
	Panuveitis	104 (27.1%)	5 (26.3%)	1.00
<b>Associated clinical signs</b>				
	Macular oedema	65 (17.0%)	1 (5.3%)	0.34
	Vasculitis	61 (15.9%)	9 (47.4%)	0.002
	Periphlebitis	1 (0.3%)	1 (5.3%)	0.092
	Unilateral papillary oedema / papillitis	80 (20.9%)	3 (15.8%)	0.78
	Bilateral papillary oedema / papillitis	35 (9.2%)	1 (5.3%)	1
<b>Diagnosis</b>				
	MS/RIS	0 (0%)	15 (78.9%)	<0.001
	OCL	10 (2.6%)	4 (23.5%)	
	Others	373 (96,9%)	0 (0.0%)	
Neurological signs		21 (5.5%)	13 (68.4%)	<0.001

Data are expressed as number and percentage, n (%), or \* median [1st; 3rd quartile].MS: multiple sclerosis; OCL: oculocerebral lymphoma; RIS: radiologically isolated syndromes

Table 4: Results of univariate and multivariate analyses

	Univariate analysis		Multivariate analysis	
	OR (95% CI)	P-value	OR (95% CI)	p-value
Intermediate uveitis	5.66 (2.10-15.3)	<0.001	4.33 (1.42-13.17)	0.010
Posterior uveitis	0.11 (0.014-0.82)	0.031		
Retinal vasculitis	4.75 (1.85-12.20)	0.002		
Periphlebitis	21.2 (1.44-401.3)	0.033		
Granulomatous	4.02 (1.58-10.2)	0.003		
Neurological signs	37.3 (12.9-108.1)	<0.0001	32.01 (10.71-95.64)	<0.001

Table 5: Oculocerebral lymphoma and multiple sclerosis characteristics compared to general population

	<b>Total</b>	<b>OCL</b>		<b>MS / RIS</b>	
	N = 402	N = 14	<b>p-value</b>	N = 15	<b>p-value</b>
Age (years) *	49 [33 ; 63]	67 [60 ; 74]	<0.001	38 [34 ; 44]	0.050
Sex (F)	230 (57.2%)	8 (57.1%)	1	11 (73.3%)	0.29
<b>Ethnicity</b>					
North Africa	50 (12.4%)	3 (21.4%)	0.64	5 (33.3%)	0.18
Sub-Saharan Africa	7 (1.7%)	0 (0.0%)		0 (0.0%)	
Caucasian	338 (84.1%)	11 (78.6%)		10 (66.7%)	
Other	7 (1.7%)	0 (0.0%)		0 (0.0%)	
<b>Anatomical type</b>					
UA	43 (10.7%)	0 (0.0%)	0.38	0 (0.0%)	0.39
UI	119 (29.6%)	7 (50.0%)	0.13	10 (66.7%)	0.003
UP	131 (32.6%)	2 (14.3%)	0.16	0 (0.0%)	0.004
PU	109 (27.1%)	5 (35.7%)	0.54	5 (33.3%)	0.56
<b>Characteristics of uveitis</b>					
Bilateral	275 (68.4%)	11 (78.6%)	0.56	11 (73.3%)	0.78
Chronic	336 (83.5%)	13 (92.9%)	0.71	14 (93.3%)	0.48
Granulomatous	93 (23.1%)	1 (7.1%)	0.2	10 (66.7%)	< 0.001
Hypertensive	23 (5.7%)	1 (7.1%)	0.57	0 (0.0%)	1
<b>Associated clinical signs</b>					
Macular oedema	66 (16.4%)	3 (21.4%)	0.71	1 (6.7%)	0.48
Retinal vasculitis	70 (17.4%)	2 (14.3%)	1	8 (53.3%)	0.001
Periphlebitis	2 (0.5%)	0 (0.0%)	1	1 (6.7%)	0.073
Unilateral papillary oedema / papillitis	83 (20.6%)	2 (14.3%)	0.74	3 (20.0%)	1
Bilateral papillary oedema / papillitis	36 (9.0%)	0 (0.0%)	0.63	1 (6.7%)	1
Contributive bMRI	19 (4.7%)	4 (28.6%)	0.003	15 (100%)	<0.001
Neurological signs	34 (8.5%)	4 (28.6%)	0.023	10 (76.7%)	<0.001

Data are expressed as number and percentage, n (%), or \* median [1st; 3rd quartile]. AU: anterior uveitis; bMRI: brain magnetic resonance imaging; IQ: Interquartile; IU: intermediate uveitis; MS: multiple sclerosis; OCL: oculocerebral lymphoma; PU: posterior uveitis; RIS: radiologically isolated syndromes; UP: panuveitis